<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Betterpath, Inc.

    Betterpath, Inc.

    Betterpath makes the benefit of health data ownership clear, reconciling crucial s...

    Betterpath makes the benefit of health data own...

    Amount Raised:    $8,800,000
    Fundraising Status:    EC
    Filing Type:    CF
    Premier, Inc.

    Premier, Inc.

    Premier operates one of the nation’s largest performance improvement alliances o...

    Premier operates one of the nation’s largest ...

    Filing Type:    PU
    The Ensign Group, Inc.

    The Ensign Group, Inc.

    The Ensign Group, Inc.'s independent operating subsidiaries provide a broad spectr...

    The Ensign Group, Inc.'s independent operating ...

    Filing Type:    PU
    Cesca Therapeutics Inc.

    Cesca Therapeutics Inc.

    Cesca is a leading regenerative medicine company that develops, commercializes and...

    Cesca is a leading regenerative medicine compan...

    Filing Type:    PU
    Pieris Pharmaceuticals, Inc.

    Pieris Pharmaceuticals, Inc.

    Pieris Pharmaceuticals, Inc. is a, clinical-stage biotechnology company committing...

    Pieris Pharmaceuticals, Inc. is a, clinical-sta...

    Filing Type:    PU
    Pluton Biosciences, LLC

    Pluton Biosciences, LLC

    Nature is full of untapped potential. Microbes are a proven but underused resource...

    Nature is full of untapped potential. Microbes ...

    Amount Raised:    $98,000.00
    Fundraising Status:    EC
    Filing Type:    CF
    Merck KGaA

    Merck KGaA

    Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates...

    Merck KGaA, Darmstadt, Germany, a leading scien...

    Filing Type:    PU
    NextCure, Inc.

    NextCure, Inc.

    NextCure is a clinical-stage biopharmaceutical company committed to discovering an...

    NextCure is a clinical-stage biopharmaceutical ...

    Filing Type:    PU
    Avalon GloboCare Corp.

    Avalon GloboCare Corp.

    Avalon GloboCare Corp. (NASDAQ: AVCO) is a global intelligent biotech developer an...

    Avalon GloboCare Corp. (NASDAQ: AVCO) is a glob...

    Filing Type:    PU
    Celgene Corporation

    Celgene Corporation

    Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global ...

    Celgene Corporation, headquartered in Summit, N...

    Filing Type:    PU
    Autolus Therapeutics plc

    Autolus Therapeutics plc

    Autolus is a clinical-stage, biopharmaceutical company, focused on the development...

    Autolus is a clinical-stage, biopharmaceutical ...

    Filing Type:    PU
    Affimed Therapeutics

    Affimed Therapeutics

    At Affimed, we are committed to improving outcomes for patients with cancer. Our s...

    At Affimed, we are committed to improving outco...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.